Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02736578 · ClinicalTrials.gov registry record · Phase 2
Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients Undergoing Surgery
A Phase 2 study, sponsored by Eben Rosenthal.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT02736578 is a Phase 2 study that was terminated before completion, run by Eben Rosenthal. The registered enrollment target is 8 participants.
The verdict
NCT02736578, a Phase 2 study, was terminated before completion, sponsored by Eben Rosenthal.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
This phase 1-2 trial studies the side effects and best dose of cetuximab-IRDye 800CW when used with intraoperative imaging, to determine the utility of cetuximab-IRDye 800CW to identify and assess pancreatic cancer in patients undergoing surgery to remove the tumor. Cetuximab-IRDye 800CW may help doctors better identify cancer in the operating room by making the cancer visible when viewed through a fluorescent imaging system.
Interventions
- DRUG Cetuximab
- DRUG Cetuximab-IRDye800
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2016-07 |
| Est. Completion | 2017-05-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02736578
The ClinicalTrials.gov registry entry for NCT02736578 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eben Rosenthal, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cetuximab is the first listed.
NCT02736578 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02736578 about?
NCT02736578 is a clinical study titled "Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients Undergoing Surgery". This phase 1-2 trial studies the side effects and best dose of cetuximab-IRDye 800CW when used with intraoperative imaging, to determine the utility of cetuximab-IRDye 800CW to identify and assess pancreatic cancer in patients undergoing surgery to remove the tumor. Cetuximab-IRDye 800CW may help do...
What is the current status of trial NCT02736578?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2016-07. Estimated completion is 2017-05-22.
What interventions are being tested in trial NCT02736578?
The interventions under investigation include: Cetuximab (DRUG), Cetuximab-IRDye800 (DRUG).
Who is sponsoring clinical trial NCT02736578?
This trial is sponsored by Eben Rosenthal, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.